Mylan (MYL) Tops Q3 EPS by 5c; Sees FY15 EPS at High End of Outlook
Mylan (NASDAQ: MYL) reported Q3 EPS of $1.43, $0.05 better than the analyst estimate of $1.38. Revenue for the quarter came in at $2.71 billion versus the consensus estimate of $2.79 billion.
Mylan CEO Heather Bresch commented, "Our outstanding third quarter results underscore the diversity of Mylan's platform and organic growth capabilities, which allows us to successfully identify and integrate strategic acquisitions and drive sustainable long-term growth and shareholder value creation. With our business continuing to hit on all cylinders, as well as the recent developments with respect to EpiPen® Auto-Injector, we are expecting to be at the high end of our 2015 guidance of $4.15 to $4.35 in adjusted diluted EPS."
*** The Street sees FY15 EPS of $4.23.
For earnings history and earnings-related data on Mylan (MYL) click here.